Kymera Therapeutics, Inc.
NASDAQKYMR arrives at its August 5 print having shed 10% over the past month to $103.40, with short sellers holding a meaningful but stable position — and the options market offering little sign of unusual anxiety. Short interest represents nearly 14% of the free float, a genuinely elevated reading for a clinical-stage biotech. Yet that position has barely moved — up less than 1% on the…
Snapshot as of 6 Aug 2026
KYMR arrives at its August 5 print having shed 10% over the past month to $103.40, with short sellers holding a meaningful but stable position — and the options market offering little sign of unusual anxiety. Short…
Kymera Therapeutics enters its May 7 earnings call with two forces pulling in opposite directions: short sellers have been cutting exposure for six weeks, yet options traders are more defensively positioned than they…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for KYMR — free to start on ORTEX.
Sign up for free →Open KYMR on ORTEX